SCHEMBL1040286

SCHEMBL1040286

CN(C)Cc1c(C(=O)NC2CCCCC2)nc(-c2ccc(Cl)cc2Cl)n1-c1ccc(Cl)cc1

nearest known ligand 0.75

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
CNR1 P21554 19/20 0.75
CNR2 P34972 16/20 0.75
OPRL1 P41146 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1037763 0.92 CNR1 (0.71) CNR1CNR2OPRL1
SCHEMBL6700506 0.90 CNR1 (0.79) CNR1CNR2
SCHEMBL6704796 0.86 CNR1 (1.00) CNR1CNR2OPRL1
SCHEMBL4499547 0.86 CNR1 (1.00) CNR1CNR2OPRL1
SCHEMBL1041298 0.86 CNR1 (0.72) CNR1CNR2
SCHEMBL674942 0.85 CNR1 (0.71) CNR1CNR2
SCHEMBL4496279 0.85 CNR1 (1.00) CNR1CNR2OPRL1
SCHEMBL4923230 0.85 CNR1 (0.70) CNR1CNR2
SCHEMBL1041935 0.85 CNR1 (0.81) CNR1CNR2
SCHEMBL6702051 0.84 CNR1 (0.70) CNR1CNR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1675833-B1 1H-IMIDAZOLE DERIVATIVES AS CANNABINOID RECEPTOR MODULATORS ABBOTT HEALTHCARE PRODUCTS BV (NL) 2011-01-26 EP disclosed
EP-1675833-B1 1H-IMIDAZOLE DERIVATIVES AS CANNABINOID RECEPTOR MODULATORS ABBOTT HEALTHCARE PRODUCTS BV (NL) 2011-01-26 EP disclosed
US-7498348-B2 1 H-imidazole derivatives as cannabinoid receptor modulators SOLVAY PHARMACEUTICALS, INC. 2009-03-03 US disclosed
US-7498348-B2 1 H-imidazole derivatives as cannabinoid receptor modulators SOLVAY PHARMACEUTICALS, INC. 2009-03-03 US disclosed
US-7498348-B2 1 H-imidazole derivatives as cannabinoid receptor modulators SOLVAY PHARMACEUTICALS, INC. 2009-03-03 US disclosed
US-20070281974-A1 1 H-IMIDAZOLE DERIVATIVES AS CANNABINOID RECEPTOR MODULATORS SOLVAY PHARMACEUTICALS, INC. 2007-12-06 US disclosed
US-20070281974-A1 1 H-IMIDAZOLE DERIVATIVES AS CANNABINOID RECEPTOR MODULATORS SOLVAY PHARMACEUTICALS, INC. 2007-12-06 US disclosed
US-20070281974-A1 1 H-IMIDAZOLE DERIVATIVES AS CANNABINOID RECEPTOR MODULATORS SOLVAY PHARMACEUTICALS, INC. 2007-12-06 US disclosed
US-7271189-B2 1H-imidazole derivatives as cannabinoid receptor modulators SOLVAY PHARMACEUTICALS, INC. (NL) 2007-09-18 US disclosed
US-7271189-B2 1H-imidazole derivatives as cannabinoid receptor modulators SOLVAY PHARMACEUTICALS, INC. (NL) 2007-09-18 US disclosed
EP-1675833-A1 1H-IMIDAZOLE DERIVATIVES AS CANNABINOID RECEPTOR MODULATORS Solvay Pharmaceuticals B.V. (NL) 2006-07-05 EP disclosed
US-20050137197-A1 1H-imidazole derivatives as cannabinoid receptor modulators ABBVIE B.V. (NL) 2005-06-23 US disclosed
WO-2005040130-A1 1H-IMIDAZOLE DERIVATIVES AS CANNABINOID RECEPTOR MODULATORS SOLVAY PHARMACEUTICALS B.V. (NL) 2005-05-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050137197-A1 1H-imidazole derivatives as cannabinoid receptor modulators CNR1, CNR2, HRH4 CNR1 1/4885CNR2 2/4885OPRL1 22/4885
US-20070281974-A1 1 H-IMIDAZOLE DERIVATIVES AS CANNABINOID RECEPTOR MODULATORS CNR1, CNR2, HRH4 CNR1 1/4885CNR2 2/4885OPRL1 40/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.